65 filings
Page 2 of 4
8-K
mkjpo
15 Sep 21
Departure of Directors or Certain Officers
8:10am
8-K
38wsfotp
5 Aug 21
Jounce Therapeutics Reports Second Quarter 2021 Financial Results
6:37am
8-K
udmpbu ega1qjw5
23 Jun 21
Submission of Matters to a Vote of Security Holders
4:42pm
8-K
yrh2cv3
4 May 21
Jounce Therapeutics Reports First Quarter 2021 Financial Results
7:09am
8-K
tezam 97thl
10 Mar 21
Jounce Therapeutics Announces Proposed Offering of Common Stock
4:48pm
8-K
rrrvotzxfwln8z s4
25 Feb 21
Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
6:39am
8-K
hmm crctvkx1eq
12 Feb 21
Departure of Directors or Certain Officers
8:14am
8-K
l5ax6d86mxtjegs6296l
11 Jan 21
Results of Operations and Financial Condition
6:11am
8-K
6jld98f
6 Nov 20
Jounce Therapeutics Reports Third Quarter 2020 Financial Results
7:11am
8-K
tjpbk
2 Nov 20
Jounce Therapeutics Announces Update on Vopratelimab Program
7:04am
8-K
p34a 8uhpzm1u54m
1 Sep 20
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program
8:38am
8-K
6zxdpa5
7 Aug 20
Jounce Therapeutics Reports Second Quarter 2020 Financial Results
6:48am
8-K
pb5emt
29 Jun 20
Submission of Matters to a Vote of Security Holders
12:00am
8-K
ybz7c90pndmu 3jsv
4 Jun 20
Entry into a Material Definitive Agreement
8:07am
8-K
0fjrgy2a
6 May 20
Jounce Therapeutics Reports First Quarter 2020 Financial Results
7:15am
8-K
3rfvuw gjubcan
7 Apr 20
Regulation FD Disclosure
7:55am
8-K
clnl251qlsg3 1y1
27 Feb 20
Jounce Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
7:15am
8-K
lrdeoxe bph
23 Jan 20
Departure of Directors or Certain Officers
8:05am
8-K
jdwnecmnwqtlm8vjoe4n
13 Jan 20
Results of Operations and Financial Condition
8:01am
8-K
586zf
17 Dec 19
Entry into a Material Definitive Agreement
5:00pm